Revolutionary Liposomal Formulation Technology
Our proprietary technology harnesses the power of liposomal formulations, delivering stability and efficacy in both oral and intravenous treatments.
FDA Grants J &D Pharmaceuticals the highly coveted Rare Pediatric Disease Designation and Orphan Drug Designation for its JD-004 and JD-005 molecules for Progeria and Related Laminopathies.
This is a carousel outlining featured items. Navigate using the arrow buttons.
Combining two molecules of salicylic acid and adding liposomal technology is our revolutionary advantage over all current analgesics.
Our proprietary technology harnesses the power of liposomal formulations, delivering stability and efficacy in both oral and intravenous treatments.
Discover how our innovative solution offers safe and effective relief from traumatic brain injury, burns, and operative pain.
To discover, rediscover, develop, and deliver safe, novel, and effective treatments that assist patients and doctors in conquering serious diseases such as traumatic brain injury, burns, and operative pain.
